Search results

1

Assessment of DNA damage profile and oxidative /antioxidative biomarker level in patients with inflammatory bowel disease

100%

Mrowicka M., Mrowicki J., Mik M., Dziki Ł., Dziki A., Majsterek I.

Polish Journal of Surgery

|

2020

|

vol. 92(5)

8-14

EN

Aim: The purpose of this study was to investigate the oxidative DNA damage, pro-antioxidant status in Polish patients with inflammatory bowel disease (IBD). Methods: Oxidative DNA damage was measured by comet assay techniques; nitric oxide (NO) and plasmatic lipid peroxidation (MDA) as oxidative stress were valuated by colometric methods; superoxide dismutase (SOD1), catalase (CAT) and glutathione peroxidase (GPx1) as antioxidative defense were determined by spectrophotometric methods. Results: The level of oxidative DNA damage in IBD patients was significantly higher in relation to controls (P = 0.01). Alike, in control subject as well as in patients with IBD, lymphocytes are characterized by complete repair of DNA damage. A significant decrease of SOD (P = 0.031), CAT (P = 0.006), GPx1 (P = 0.001) activity was seen in IBD patients vs control. MDA (P = 0.001) and NO (P = 0.001) concentrations were significantly increased in IBD patients as compared to healthy subjects. Conclusions: Our results may be due to the induction of DNA repair genes which may occur at the stage of the pathological changes (IBD) that may be caused by excessive oxidative stress. However, the cause of this relationship, and whether it is direct or indirect, remains to be explored.

2

Activity and kinetic properties of phosphotransacetylase from intestinal sulfate-reducing bacteria

100%

Kushkevych I.

|

issue 1

103-108

EN

Phosphotransacetylase activity and the kinetic properties of the enzyme from intestinal sulfate-reducing bacteria Desulfovibrio piger and Desulfomicrobium sp. has never been well-characterized and has not been studied yet. In this paper, the specific activity of phosphotransacetylase and the kinetic properties of the enzyme in cell-free extracts of both D. piger Vib-7 and Desulfomicrobium sp. Rod-9 intestinal bacterial strains were presented at the first time. The microbiological, biochemical, biophysical and statistical methods in this work were used. The optimal temperature and pH for enzyme reaction was determined. Analysis of the kinetic properties of the studied enzyme was carried out. Initial (instantaneous) reaction velocity (V0), maximum amount of the product of reaction (Pmax), the reaction time (half saturation period, τ) and maximum velocity of the phosphotransacetylase reaction (Vmax) were defined. Michaelis constants (Km) of the enzyme reaction (3.36 ± 0.35 mM for D. piger Vib-7, 5.97 ± 0.62 mM for Desulfomicrobium sp. Rod-9) were calculated. The studies of the phosphotransacetylase in the process of dissimilatory sulfate reduction and kinetic properties of this enzyme in intestinal sulfate-reducing bacteria, their production of acetate in detail can be perspective for clarification of their etiological role in the development of the humans and animals bowel diseases. These studies might help in predicting the development of diseases of the gastrointestinal tract, by providing further details on the etiology of bowel diseases which are very important for the clinical diagnosis of these disease types.

3

Association of the-801G/A Polymorphism ofCXCL12Gene with the Risk of Inflammatory Bowel Diseases Development in a Polish Population

88%

Mrowicki J., Przybyłowska K., Dziki Ł., Sygut A., Wiśniewska-Jarosińska M., Chojnacki J., Dziki A., Majsterek I.

|

EN

Inflammatory bowel diseases (IBDs), mainly ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic and idiopathic inflammatory conditions of gastrointestinal tract that are immunologically mediated. Stromal cell-derived factor 1 (CXCL12) has been demonstrated to be involved in the pathophysiology of IBD.The aim of the study was to investigate whether the CXCL12 -G/A polymorphism (rs1801157) is associated to IBD in a sample of Polish population.Material and methods. A total of 188 patients with IBD including 103 patients with CU and 72 patients with CD and 184 controls were enrolled in the study. Both groups came from the Polish population. The G/A polymorphism of CXCL12 was determined by PCR-RFLP analysis.Results. There was no association between G/A polymorphism at position -801 promoter region of CXCL12 gene and increased risk of IBD. The study population was not found a difference in genotype distribution between the control group and with both CD and CU patients.Conclusions. These results suggest that G/A polymorphism at position -801 promoter region of CXCL12 gene relates neither to the risk of the development of inflammatory bowel disease nor to the clinical subtypes of IBD in the Polish population. Whether this polymorphism truly contributes to disease susceptibility needs to be further addressed, and should stimulate additional studies in other populations.

4

Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity

75%

Czub E., Nowak J., Szaflarska-Poplawska A., Grzybowska-Chlebowczyk U., Landowski P., Moczko J., Adamczak D., Mankowski P., Banasiewicz T., Plawski A., Walkowiak J.

Acta Biochimica Polonica

|

2014

|

vol. 61

|

issue 1

99-102

EN

Aims: Accurate assessment of inflammatory bowel disease (IBD) activity is the cornerstone of effective therapy. Fecal M2 isoform of pyruvate kinase (M2-PK) and fecal calprotectin (FC) are noninvasive markers of mucosal inflammation in IBD. The aim of this study was to compare performance of M2-PK and FC in assessment of pediatric ulcerative colitis (UC) and Crohn's disease (CD) severity and activity. Materials and methods: 121 patients with IBD, including 75 with UC and 46 with CD were recruited. Control group consisted of 35 healthy children (HS). Patients were assigned to groups depending on disease severity and activity. M2-PK and calprotectin concentration were determined in stool samples using ELISA. Areas under receiver operating characteristic curves (AUC) for FC and M2-PK with cut-off level at which M2-PK specificity was matching FC specificity were calculated and compared. Results: Performance of M2-PK at identifying patients with IBD, UC and CD among HS was inferior to FC. The differences in AUC were respectively: -0.10 (95% confidence interval [CI] [-0.13-(-0.06)], p<0.0001), -0.14 (95% CI [-0.19-(-0.09)], p<0.0001) and -0.03 (95% CI [-0.05-(-0.001)], p<0.02). M2-PK was inferior to FC in discriminating patients with mild UC from those with HS (AUC difference -0.23, 95% CI [-0.31-(-0.15)], p<0.0001). Conclusions: FC reflects pediatric IBD severity and activity better than M2-PK. This difference is particularly pronounced when identifying patients with mild UC and UC in remission.

5

The therapeutic potential of short-chain fatty acids enemas in inflammatory bowel diseases: a systematic review

63%

Kaczmarek N., Kokot M., Makarewicz A., Glapa-Nowak A., Nowak J. K., Jamka M., Walkowiak J.

Farmacja Polska

|

2020

|

vol. 76

|

issue 5

297-304

PL

Sugeruje się, że krótkołańcuchowe kwasy tłuszczowe (SCFA) mogą redukować nasilenie objawów klinicznych, poprawiać wyniki badania endoskopowego i histopatologicznego u pacjentów z nieswoistymi chorobami zapalnymi jelit (IBD). Jednakże, pomimo obiecujących badań in vitro, wyniki badań przeprowadzonych w modelu zwierzęcym oraz randomizowanych badań kontrolowanych (RCT) są niejednoznaczne. Celem tego przeglądu systematycznego była ocena skuteczności SCFA podawanych doodbytniczo u pacjentów z IBD. Wyszukiwanie elektroniczne przeprowadzono w następujących bazach danych: PubMed, Scopus, Web of Science i Cochrane. Kryteria włączenia badań oryginalnych do przeglądu systematycznego obejmowały: 1) rodzaj badań: równoległe lub krzyżowe RCT; 2) język: artykuły w języku angielskim; 3) rodzaj interwencji: SCFA podawane doodbytniczo; 4) populacja badana: pacjenci z wrzodziejącym zapaleniem jelita grubego lub chorobą Leśniowskiego-Crohna, niezależnie od płci, wieku, pochodzenia etnicznego, lokalizacji badania i wielkości próby. Jako punkty końcowe przyjęto wpływ podaży SCFA na wskaźnik aktywności choroby (DAI) oraz wyniki badań endoskopowych i histopatologicznych. Do analizy zakwalifikowano 4 badania obejmujące łącznie 187 pacjentów z IBD. W 2 badaniach oceniano wpływ SCFA na DAI, w 4 badaniach – na wyniki badania endoskopowego i histopatologicznego. Nie stwierdzono istotnych różnic pomiędzy grupą interwencyjną a grupą kontrolną w zakresie wpływu na jakikolwiek analizowany parametr. W 2 badaniach wykazano istotny spadek DAI po okresie interwencji, zarówno w grupie SCFA, jak i w grupie kontrolnej. Podobnie, w 4 badaniach odnotowano statystycznie istotne różnice między wynikami endoskopowymi przed i po interwencji w grupie SCFA. Jednakże, w 3 badaniach podobny efekt zaobserwowano w grupie kontrolnej. Poza tym, w 3 badaniach nie zaobserwowano wpływu SCFA na wyniki histopatologiczne. Podsumowując, brak jest dowodów na skuteczność SCFA podawanych doodbytniczo u pacjentów z IBD.

EN

It has been suggested that short-chain fatty acid (SCFA) enemas might improve clinical, endoscopic and histological scores in patients with inflammatory bowel disease. However, despite the promising results of in vitro studies, the findings of animal studies and randomised controlled trials are inconclusive. Therefore, this review aimed to assess the efficacy of SCFA enemas in patients with inflammatory bowel diseases. Electronic searches were performed in PubMed, Scopus, Web of Science and Cochrane databases. Original studies were included in this systematic review if they met the following inclusion criteria: 1) types of studies: parallel or crossover randomised controlled trials; 2) language: articles published in English; 3) types of interventions: SCFA enemas; 4) population: studies conducted in subjects with ulcerative colitis or Crohn’s disease of either gender and any age and without restrictions based on the ethnicity of study participants, location of study or sample size. The outcomes included the effect of SCFA enemas on disease activity index (DAI), endoscopic and histological scores. In total, four studies enrolling 187 patients with inflammatory bowel diseases were included in this systematic review. Two studies assessed the effect of SCFA enemas on DAI. Four studies evaluated the effect of SCFA therapy on the endoscopic score and the histological score. There were no significant differences between the SCFA groups and the control groups regarding the impact on any analysed parameter. Two studies demonstrated a statistically significant decrease in DAI after the intervention period, both in the SCFA groups and the control groups. Similarly, statistically significant differences between pre- and post-intervention endoscopic scores in the SCFA groups were reported in four studies. However, in three studies, a similar effect was demonstrated in the control groups. Besides, in three studies no effect of SCFA enemas on the histological score was observed. In conclusion, there is no evidence for the effectiveness of SCFA enemas in patients with inflammatory bowel diseases.

Refine search results

Assessment of DNA damage profile and oxidative /antioxidative biomarker level in patients with inflammatory bowel disease

Activity and kinetic properties of phosphotransacetylase from intestinal sulfate-reducing bacteria

Association of the-801G/A Polymorphism ofCXCL12Gene with the Risk of Inflammatory Bowel Diseases Development in a Polish Population

Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity

The therapeutic potential of short-chain fatty acids enemas in inflammatory bowel diseases: a systematic review